A review of perioperative treatment strategies with immunotherapy and tyrosine kinase inhibitors in resectable and stage IIIA-N2 non-small cell lung cancer
Stage IIIA-N2 non-small cell lung cancer (NSCLC) is a heterogeneous group with different potential therapeutic approaches. Treatment is typically multimodal with either surgical resection after neoadjuvant chemotherapy and/or radiation or concurrent chemotherapy and radiation if unresectable. Despit...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1373388/full |
| _version_ | 1797242874820034560 |
|---|---|
| author | Madeleine B. Hopson Sawsan Rashdan |
| author_facet | Madeleine B. Hopson Sawsan Rashdan |
| author_sort | Madeleine B. Hopson |
| collection | DOAJ |
| description | Stage IIIA-N2 non-small cell lung cancer (NSCLC) is a heterogeneous group with different potential therapeutic approaches. Treatment is typically multimodal with either surgical resection after neoadjuvant chemotherapy and/or radiation or concurrent chemotherapy and radiation if unresectable. Despite the multimodal treatment and early stage, cure rates have traditionally been low. The introduction of immunotherapy changed the treatment landscape for NSCLC in all stages, and the introduction of immunotherapy in early-stage lung cancer has improved event free survival and overall survival. Tyrosine Kinase inhibitors (TKIs) have also improved outcomes in early-stage mutation-driven NSCLC. Optimal treatment choice and sequence is increasingly becoming based upon personalized factors including clinical characteristics, comorbidities, programmed death-ligand 1 (PD-L1) score, and the presence of targetable mutations. Despite encouraging data from multiple trials, the optimal multimodal sequence of stage IIIA-N2 NSCLC treatment remains unresolved and warrants further investigation. This review article summarizes recent major clinical trials of neoadjuvant and adjuvant treatment including stage IIIA-N2 NSCLC with a focus on immunotherapy and TKIs. |
| first_indexed | 2024-04-24T18:46:10Z |
| format | Article |
| id | doaj.art-4371ee8808d44015b5ff6c891e5dc4e6 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-24T18:46:10Z |
| publishDate | 2024-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-4371ee8808d44015b5ff6c891e5dc4e62024-03-27T05:09:40ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-03-011410.3389/fonc.2024.13733881373388A review of perioperative treatment strategies with immunotherapy and tyrosine kinase inhibitors in resectable and stage IIIA-N2 non-small cell lung cancerMadeleine B. Hopson0Sawsan Rashdan1Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United StatesHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, United StatesStage IIIA-N2 non-small cell lung cancer (NSCLC) is a heterogeneous group with different potential therapeutic approaches. Treatment is typically multimodal with either surgical resection after neoadjuvant chemotherapy and/or radiation or concurrent chemotherapy and radiation if unresectable. Despite the multimodal treatment and early stage, cure rates have traditionally been low. The introduction of immunotherapy changed the treatment landscape for NSCLC in all stages, and the introduction of immunotherapy in early-stage lung cancer has improved event free survival and overall survival. Tyrosine Kinase inhibitors (TKIs) have also improved outcomes in early-stage mutation-driven NSCLC. Optimal treatment choice and sequence is increasingly becoming based upon personalized factors including clinical characteristics, comorbidities, programmed death-ligand 1 (PD-L1) score, and the presence of targetable mutations. Despite encouraging data from multiple trials, the optimal multimodal sequence of stage IIIA-N2 NSCLC treatment remains unresolved and warrants further investigation. This review article summarizes recent major clinical trials of neoadjuvant and adjuvant treatment including stage IIIA-N2 NSCLC with a focus on immunotherapy and TKIs.https://www.frontiersin.org/articles/10.3389/fonc.2024.1373388/fulllung cancerimmunotherapytyrosine kinase inhibitorsadjuvantneoadjuvantearly-stage |
| spellingShingle | Madeleine B. Hopson Sawsan Rashdan A review of perioperative treatment strategies with immunotherapy and tyrosine kinase inhibitors in resectable and stage IIIA-N2 non-small cell lung cancer Frontiers in Oncology lung cancer immunotherapy tyrosine kinase inhibitors adjuvant neoadjuvant early-stage |
| title | A review of perioperative treatment strategies with immunotherapy and tyrosine kinase inhibitors in resectable and stage IIIA-N2 non-small cell lung cancer |
| title_full | A review of perioperative treatment strategies with immunotherapy and tyrosine kinase inhibitors in resectable and stage IIIA-N2 non-small cell lung cancer |
| title_fullStr | A review of perioperative treatment strategies with immunotherapy and tyrosine kinase inhibitors in resectable and stage IIIA-N2 non-small cell lung cancer |
| title_full_unstemmed | A review of perioperative treatment strategies with immunotherapy and tyrosine kinase inhibitors in resectable and stage IIIA-N2 non-small cell lung cancer |
| title_short | A review of perioperative treatment strategies with immunotherapy and tyrosine kinase inhibitors in resectable and stage IIIA-N2 non-small cell lung cancer |
| title_sort | review of perioperative treatment strategies with immunotherapy and tyrosine kinase inhibitors in resectable and stage iiia n2 non small cell lung cancer |
| topic | lung cancer immunotherapy tyrosine kinase inhibitors adjuvant neoadjuvant early-stage |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1373388/full |
| work_keys_str_mv | AT madeleinebhopson areviewofperioperativetreatmentstrategieswithimmunotherapyandtyrosinekinaseinhibitorsinresectableandstageiiian2nonsmallcelllungcancer AT sawsanrashdan areviewofperioperativetreatmentstrategieswithimmunotherapyandtyrosinekinaseinhibitorsinresectableandstageiiian2nonsmallcelllungcancer AT madeleinebhopson reviewofperioperativetreatmentstrategieswithimmunotherapyandtyrosinekinaseinhibitorsinresectableandstageiiian2nonsmallcelllungcancer AT sawsanrashdan reviewofperioperativetreatmentstrategieswithimmunotherapyandtyrosinekinaseinhibitorsinresectableandstageiiian2nonsmallcelllungcancer |